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Abstract 
Purpose: Fatigue is the most common and distressing symptom reported by 
cancer patients during and after treatment. Tumor growth increases oxidative 
stress and cytokine production, which causes skeletal muscle wasting and 
cardiac dysfunction. The purpose of this study was to determine whether 
treatment with the antioxidant ubiquinol improves muscle mass, cardiac 
function, and behavioral measures of fatigue in tumor-bearing mice. 
Method: Adult female mice were inoculated with colon26 tumor cells. Half the 
control and tumor-bearing mice were administered ubiquinol (500 
mg/kg/day) in their drinking water. Voluntary wheel running (i.e., voluntary 
running activity [VRA]) and grip strength were measured at Days 0, 8, 14, 
and 17 of tumor growth. Cardiac function was measured using 
echocardiography on Day 18 or 19. Biomarkers of inflammation, protein 
degradation, and oxidative stress were measured in serum and heart and 
gastrocnemius tissue. 
Results: VRA and grip strength progressively declined in tumor-bearing mice. 
Muscle mass and myocardial diastolic function were decreased, and 
expression of proinflammatory cytokines was increased in serum and muscle 
and heart tissue on Day 19 of tumor growth. Oxidative stress was present 
only in the heart, while biomarkers of protein degradation were increased only 
in the gastrocnemius muscle. Ubiquinol increased muscle mass in the tumor-
bearing and control animals but had no effect on the expression of biomarkers 
of inflammation, protein degradation, or oxidative stress or on behavioral 
measures of fatigue. 
Keywords: cancer-related fatigue, ubiquinol, tumor growth, mice, colon26 
adenocarcinoma, oxidative stress 
Cancer patients report that the symptom of fatigue is more 
distressing than that of pain, nausea, or vomiting (Berger et al., 
2010). Fatigue can be present at diagnosis, increases during 
treatment, and can persist for years after treatment is completed. 
Cancer-related fatigue (CRF) impairs the patient’s functional ability 
and affects employment status (Amir, Wilson, Hennings, & Young, 
2012; Minton et al., 2013; Munir, Yarker, & McDermott, 2009) and, in 
patients with persistent tumor disease, is associated with loss of lean 
body (muscle) mass and reduced effort tolerance (Martin et al., 2013; 
Weber et al., 2009). The causes of CRF are not clearly understood, and 
treatment is largely intuitive (Dantzer, Meagher, & Cleeland, 2013; 
Dodson et al., 2011). 
Disturbances in regulation of the hypothalamic–pituitary–
adrenal axis, serotonin synthesis, and circadian rhythms (Barsevik et 
al., 2010; Silverman, Heim, Nater, Marques, & Sternberg, 2010) have 
all been implicated in the pathobiology of CRF. There is also a 
significant body of literature implicating increased host or tumor 
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production of proinflammatory cytokines (Liu et al., 2012; Saligan & 
Kim, 2012; Wang et al., 2012) and reactive oxygen species (ROS; 
Gilliam & St. Clair, 2011; Reid & Moylan, 2011) in the pathobiology of 
CRF, particularly in tumor-induced skeletal muscle wasting (Suzuki, 
Asakawa, Amitani, Nakamura, & Inui, 2013; van Hall, 2012) and 
cardiac dysfunction (Marin-Corral et al., 2010; Mazevet et al., 2013). 
Tumor necrosis factor α (TNF-α) acts via the type I receptor for TNF-α 
(TNFR1) to activate intracellular pathways involved in muscle wasting, 
including the ubiquitin proteosome ATP-dependent pathway (UPP) and 
the autophagy–lysosome system (ALS; Fearon, Glass, & Guttridge, 
2012; Sandri, 2013). MuRF1 and MAFbx are two ligases in the UPP 
that ubiquinate myofibrillar proteins to be degraded in the proteasome 
(Foletta, White, Larsen, Leger, & Russell, 2011). BNIP3 is involved in 
the formation of phagosomes and increased activity of the ALS (Bellot 
et al., 2009). Skeletal muscle expression of MAFbx, MuRF1, and BNIP3 
messenger RNA (mRNA) is increased in tumor-bearing mice (Tian, 
Asp, Nishijima, & Belury, 2011; Xu et al., 2011), though evidence from 
muscle biopsies of cancer patients is inconsistent (D’Orlando et al., 
2014; Sun, Ye, Qian, Xu, & Hu, 2012; V. E. Baracos to D.O.M., 
personal communication, October 11, 2013). 
Proinflammatory cytokines also increase the production of ROS 
in target tissues (Reid & Moylan, 2011). Increased oxidant activity is 
associated with increased expression of MuRF-1, MAFbx, and BNIP3 
mRNA and skeletal muscle wasting (Suzuki et al., 2013). Researchers 
have also described evidence of oxidative damage to proteins affecting 
contraction, glycolysis, and mitochondrial metabolism in the heart as 
well as in the skeletal muscle of tumor-bearing animals (Marin-Corral 
et al., 2010; Tian et al., 2010). These studies suggest that oxidative 
stress may be a potential target for reducing skeletal muscle wasting 
and perhaps CRF. 
Ubiquinone (CoQ10) is an endogenously synthesized, lipid-
soluble antioxidant. Tissue levels of CoQ10 are decreased in patients 
with lung, melanoma, and cervical cancer compared to healthy 
controls (Cobanoglu et al., 2011; Rusciani et al., 2006). Treatment 
with CoQ10 has been shown to reduce chemotherapy-induced 
cardiotoxicity and nephrotoxicity in healthy mice (El-Sheikh, Morsy, 
Mahmoud, Rifaai, & Abdelrahman, 2012; Fouad, Al-Sultan, Refaie, & 
Yacoubi, 2010). The effects of CoQ10 or ubiquinol, the reduced form of 
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CoQ10, on tumor-induced oxidative stress, muscle wasting, and 
myocardial dysfunction have not been studied. The purpose of the 
present study was to determine the effects of ubiquinol treatment on 
skeletal muscle mass, myocardial function, expression of biomarkers 
of inflammation, oxidative stress, protein degradation, and behavioral 
measures of fatigue in a mouse model of CRF. 
Method 
A total of 64 adult female CD2F1 mice (Charles River) were 
randomly assigned to one of four groups (tumor/no drug, tumor + 
drug, control/no drug, and control + drug). A power analysis using 
data from pilot work indicated that 16 mice per group were needed to 
detect a moderate effect size of ubiquinol on muscle mass. Three 
experiments were conducted using 18–24 animals in each experiment, 
and the data were pooled. All procedures were approved by the 
Institutional Animal Care and Use Committee of the Ohio State 
University and were conducted according to the National Institutes of 
Health Guide for the Care and Use of Laboratory Animals. 
All mice were maintained on a 12-hr light–dark cycle and 
housed individually. Tumor growth was induced using the colon26 
murine tumor cell line. This tumor cell line secretes interleukin 6 (IL-6) 
and TNF-α (Graves, Ramsay, & McCarthy, 2006) and does not 
metastasize when injected subcutaneously (Okayama et al., 2009). It 
is frequently used to model the systemic effects of tumor growth on 
skeletal muscle, heart, gut, and skin (Cosper & Leinwand, 2011; 
Murphy, Chee, Trieu, Naim, & Lynch, 2012; Redon et al., 2010; 
Shadfar et al., 2011; Tian et al., 2011). The gastrocnemius is most 
often used to study the effects of tumor growth on skeletal muscle 
because it contains both slow- and fast-twitch fibers. 
On Day 0, a total of 32 mice were injected subcutaneously 
between the scapulae with 5 × 105 of colon26 cells suspended in 0.2 
ml of saline, as previously described (Xu et al., 2011), and 32 control 
animals were injected with 0.2 ml saline alone. On Day 1, half of the 
control (n = 16) and half of the tumor-bearing mice (n = 16) received 
a 2% solution of ubiquinol (Kaneka Nutrients L.P., Pasadena, CA) in 
their drinking water; the other half of the tumor-bearing and control 
mice received a control solution provided by the manufacturer in their 
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drinking water. The concentration was based on delivering a dose of 
500 mg/kg/day in a volume of 4–5 ml, the average volume of fluid 
consumed by 20-g mice. This dose was previously shown to reduce 
inflammatory gene transcripts in a mouse model of aging (Schmelzer 
et al., 2010). Fluid intake was measured every 3 days by weighing the 
sipper bottles before and after placement of fresh food and water. 
Fatigue was modeled as reduced voluntary running activity 
(VRA; Wood, Nail, Gilster, Winters, & Elsea, 2006; Zombeck, Fey, 
Lyng, & Sonis, 2013). Running wheels (4 in.) were placed inside each 
cage and connected to a computer and data processor (Columbus 
Instruments, Columbus, OH). Mice were acclimated to the running 
wheels for 1 week prior to tumor cell injection. Total wheel turns were 
recorded for 24 hr on Days 0, 8, 14, and 17 of tumor growth to 
capture the onset of changes in VRA in relation to tumor growth. 
Weakness was modeled as reduced forelimb grip strength 
(Murphy et al., 2012) using an automated grip strength meter 
(Columbus Instruments). Grip strength was measured on Days 0, 8, 
14, and 17 of tumor growth. Each mouse was lowered vertically by its 
tail until the forelimbs rested on the grid and then pulled horizontally 
until it dislodged from the grid. Three measurements were taken and 
averaged to determine the grams of force required to dislodge the 
mouse from the grid. Because smaller mice would be expected to 
generate less grip strength, this measure was normalized to body 
weight (Murphy et al., 2012). 
Echocardiography was performed on Day 18 or 19 using a 
VisualSonics Vivo 2100 Ultra High Resolution In Vivo Imaging System 
(VisualSolics, Toronto, Ontario, Canada), as previously described 
(Tournoux et al., 2011; Xu et al., 2011). Scanning was performed at a 
frequency of 20 MHz, and three total measures were averaged from 
different points within the cardiac cycle according to the standards set 
forth by the American Society for Echocardiography. M-mode images 
were obtained at the level of the papillary muscles to assess left 
ventricular systolic diameter (LVSD), LV diastolic diameter (LVDD), 
isovolumetric relaxation (IVRT), and posterior wall thickness (PWT). M-
mode calculations were used to derive fractional shortening (FS = 
LVDD − LVSD/LVDD). 
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Following echocardiography, the mice were deeply anesthetized 
by injecting 2 mg of 1% ketamine/xylazine. Blood was drawn from the 
submandibular vein and placed into a micro-centrifuge tube containing 
100 μl of 0.1 M EDTA. The heart, right and left gastrocnemius muscles, 
and tumor were dissected and weighed. The muscles and heart were 
snap frozen in liquid nitrogen and stored at −80°C until biochemical 
analyses. Blood samples were centrifuged, and the serum was 
collected and stored at −20°C until analyses of cytokine levels. To 
control for variations in dissected muscle weights, the weight of the 
left and right gastrocnemius muscles were averaged to determine 
gastrocnemius muscle weight. The heart and gastrocnemius muscle 
weights were also normalized to body weight and expressed as heart 
or gastrocnemius muscle mass (mg/g). Weights of these tissues were 
also normalized to carcass weight (body weight – tumor weight). 
Serum concentrations of IL-6 and the TNFR1 were measured 
using commercially available enzyme-linked immunosorbent assay kits 
for murine TNFR1 and IL-6 (Meso Scale Discovery, Rockville, MD) 
according to the manufacturer’s instructions. All samples were tested 
in duplicate, and the results are expressed as picograms protein per 
milliliter of serum (pg/ml). Glutathione exists in cells in reduced 
sulfhydryl (GSH) and oxidized (GSSG) forms (Owen & Butterfield, 
2010). Cardiac and gastrocnemius muscle tissue (30 mg each) were 
homogenized to measure GSH and GSSG concentrations as described 
by Rahman, Kode, and Biswas (2006). Results are reported as the 
GSH/GSSG ratio. A decreased ratio indicates oxidative stress. 
Expression of BNIP3, MAFbx, MuRF1, IL-6, and TNFR1 mRNA in 
gastrocnemius and heart tissue were measured using real-time 
polymerase chain reaction (PCR). Total RNA was extracted from 30 mg 
of frozen tissue using the Fibrous Tissue Mini Kit per manufacturer’s 
instructions (Qiagen, Netherlands). RNA quantity and purity were 
checked using the Nano-Drop (Thermo Scientific, Waltham, MA), and 
quality was verified on an agarose gel. The RNA was reverse 
transcribed, and the complementary DNA was probed for expression of 
genes of interest using PCR with primer pairs specific for those genes 
as previously described (Xu et al., 2011). Expression of each gene was 
normalized to expression of glyceraldehyde-3-phosphate 
dehydrogenase. 
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Data were analyzed using two-way analysis of variance 
(ANOVA) to determine the main effects and potential interaction 
effects of tumor growth and ubiquinol treatment. Repeated-measures 
ANOVA was used to examine the effects of tumor growth and ubiquinol 
on VRA and grip strength on Days 0, 8, 14, and 17 or 18, followed by 
Bonferroni post hoc tests. Independent samples t-test was performed 
to compare tumor weights. Statistical significance was set a priori at α 
= .05. 
Results 
Tumor growth was palpable by Day 7 and did not exceed 5% of 
body weight at the time of sacrifice on Days 18–19 of tumor growth. 
As shown in Table 1, there was no effect of ubiquinol on tumor growth. 
All four groups of mice drank an average of 4 ml of water per day over 
the course of the study, and there was no effect of tumor growth or 
ubiquinol treatment on water or food intake. Tissue analysis was 
completed on all 64 animals, but only 42 animals were utilized for 
echocardiography due to scheduling issues and 46 for wheel running 
due to equipment issues. 
Table 1. Effects of Tumor Growth and Ubiquinol on Tissue Weights. 
Tissue Control n 
= 16 
M (SD) 
Control + 
drug n = 16 
M (SD) 
Tumor n 
= 16 
M (SD) 
Tumor + 
drug n = 16 
M (SD) 
Test 
statistic 
Body (g) 19.5 (1.4) 19.5 (1.4) 18.6 (1.8) 18.7 (1.5) F(1, 64) = 
5.5*, a 
Carcass (g) 19.5 (1.4) 19.5 (1.4) 17.9 (1.9) 17.9 (1.7) F(1, 64) = 
17.5***, a 
Gastrocnemius (mg) 96.8 
(12.6) 
104.4 (8.4) 78.1 
(16.3) 
83.0 (12.5) F(1, 64) = 
41.8***, a 
F(1, 64) = 
4.0*,b 
Gastrocnemius/body weight 
(mg/g) 
5.0 (.5) 5.4 (.32) 4.2 (.75) 4.4 (.5) F(1, 64) = 
40.9***, a 
F(1, 64) = 
5.5*,b 
Gastrocnemius/carcass 
weight (mg/g) 
5.0 (.5) 5.4 (.32) 4.4 (.77) 4.6 (.5) F(1, 64) = 
24.1***, a 
F(1, 64) = 
6.4*,b 
Heart (mg) 88.4 (6.3) 88.4 (4.5) 86.9 (9.7) 88.2 (7.8) ns 
Heart/body weight (mg/g) 4.6 (.41) 4.6 (.29) 4.7 (.43) 4.7 (.38) ns 
Tumor (g) – – .73 (.30) .82 (.24) ns 
Note. 
aMain effect of tumor. 
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bMain effect of drug. 
*p < .05. 
**p < .01. 
***p < .001. 
Tissue Weights 
The tumor-bearing mice weighed 5% less than healthy controls 
by Days 18–19 of tumor growth (p < .05). Carcass weight of the 
tumor-bearing mice was 9% less than that of healthy controls (p 
< .001). As shown in Table 1, there was no effect of ubiquinol on body 
weight or carcass weight of the animals. 
The weight of the gastrocnemius muscles from tumor-bearing 
mice was 20% less than muscles from control mice by Days 18–19 of 
tumor growth (p < .001), and muscle mass in tumor-bearing mice was 
16% less than in controls (p < .001). As shown in Table 1, there was a 
main effect of ubiquinol treatment (p < .05) on muscle weight and 
muscle mass. There was, however, no interaction effect. There was no 
significant effect of tumor growth or ubiquinol treatment on heart 
weight or heart mass of any of the groups of mice. 
Proinflammatory Cytokines 
As shown in Table 2, IL-6 was increased in serum of tumor-
bearing mice by Day 18 or 19 of tumor growth compared to healthy 
controls (p < .001), as was TNFR1 (p < .001). However, there was no 
effect of ubiquinol on serum levels of either cytokine. Expression of IL-
6 mRNA was increased in the gastrocnemius (p < .05) and heart tissue 
(p < .001) of tumor-bearing animals compared to healthy controls. 
Expression of TNFR1 mRNA was also increased in the gastrocnemius (p 
< .001) and heart tissue (p < .001) of tumor-bearing mice. However, 
there was no effect of ubiquinol on expression of IL-6 or TNFR1 mRNA 
in the gastrocnemius muscles or heart. 
Table 2. Inflammatory Biomarkers in Serum and Tissue. 
Inflammatory 
biomarker 
Control n 
= 16 
M (SD) 
Control + drug 
n = 16 
M (SD) 
Tumor n 
= 16 
M (SD) 
Tumor + drug 
n = 16 
M (SD) 
Test statistic 
Cytokines 
 Serum (pg/ml) 
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Inflammatory 
biomarker 
Control n 
= 16 
M (SD) 
Control + drug 
n = 16 
M (SD) 
Tumor n 
= 16 
M (SD) 
Tumor + drug 
n = 16 
M (SD) 
Test statistic 
  IL-6 9.4 (9.4) 7.9 (7.7) 241.1 
(162.8) 
240.5 (166.2) F(1, 64) = 
62.8***,a 
  TNFR1 690.3 
(251.2) 
813.4 (204.2) 1284.1 
(595.6) 
1341.1 (405.6) F(1, 64) = 
33.8***,a 
 Heart (ddct) 
  IL-6 .95 (.69) .50 (.35) 5.7 (2.9) 7.0 (5.8) F(1, 64) = 
43.6***,a 
  TNFR1 1.0 (.19) .95 (2.0) 2.2 (.60) 3.4 (2.6) F(1, 64) = 
27.1***,a 
 Gastrocnemius (ddct) 
  IL-6 1.1 (1.0) .51 (.23) 1.3 (1.0) 1.8 (2.3) F(1, 64) = 
4.2*,a 
  TNFR1 1.1 (.47) .94 (.43) 1.7 (.72) 1.7 (.64) F(1, 64) = 
22.4***,a 
GSH/GSSG (μM) 
 Heart 6.8 (3.5) 5.9 (2.1) 3.2 (.6) 3.3 (.78) F(1, 60) = 
34.5***,a 
 Gastrocnemius 5.2 (1.2) 4.9 (1.3) 4.1 (1.3) 4.9 (1.3) ns 
Note. ddct = relative to expression of GAPDH; GADPH = glyceraldehyde-3-phosphate 
dehydrogenase; IL = interleukin; GSH/GSSG = ratio of reduced sulfhydryl glutathione 
to oxidized glutathione; TNFR1 = tumor necrosis factor-α type 1 receptor. 
aMain effect of tumor. 
*p < .05. 
**p < .01. 
***p < .001. 
Oxidative Stress 
The GSH/GSSH ratio was decreased 18% in the gastrocnemius 
muscle of the tumor-bearing mice but was not significantly different 
from that of the controls (p = .06). However, the GSH/ GSSH ratio 
was decreased 53% in the hearts of tumor-bearing mice and was 
significantly different from that in the heart tissue of control mice (p 
< .001). As shown in Table 2, there was no effect of ubiquinol 
treatment on the GSH/GSSG ratio in gastrocnemius or heart tissue. 
Protein Degradation 
Expression of MAFbx mRNA in the gastrocnemius muscle of 
tumor-bearing mice was increased on Day 18 or 19 of tumor growth 
compared to its expression in the muscles of control animals, F(1, 64) 
= 22.1, p < .01, as was the expression of MuRF1 (p < .01) and BNIP3 
mRNA (p < .01). In contrast, expression of MAFbx, MuRF1, and BNIP3 
mRNA was not significantly increased in heart tissue of the tumor-
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bearing mice. In spite of the increase in muscle mass of the animals 
described earlier, there was no effect of ubiquinol on expression of 
these biomarkers of protein degradation in gastrocnemius or heart 
tissue. Data are shown in Figure 1. 
 
Figure 1. Effect of tumor growth and ubiquinol on expression of MAFbx, MuRF1, and 
BNIP3 mRNA in gastrocnemius muscle (a) and heart (b). Main effect of tumor in 
gastrocnemius, p < .01. CC = control no drug, n = 16; CU = control/ubiquinol, n = 
16; TC = tumor no drug, n = 16; TU = tumor/ubiquinol, n = 16. 
Myocardial Function 
Neither tumor growth nor ubiquinol had a significant effect on 
LVDD, LVSD, PWT, or FS on Day 18 or 19 of tumor growth. However, 
IVRT was significantly increased in the tumor-bearing mice, F(1, 38) = 
9.32, p < .01, compared to the control mice. There was no effect of 
ubiquinol on IVRT. Data are shown in Table 3. 
Table 3. The Effects of Tumor Growth and Ubiquinol on Myocardial Function. 
Myocardial function 
(mm) 
Control 
M (SD) 
Control + 
drug 
M (SD) 
Tumor 
M (SD) 
Tumor + 
drug 
M (SD) 
Test statistic 
LVDD 3.5 (.30) 2.7 (1.5) 3.0 (1.5) 2.8 (1.8) ns 
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Myocardial function 
(mm) 
Control 
M (SD) 
Control + 
drug 
M (SD) 
Tumor 
M (SD) 
Tumor + 
drug 
M (SD) 
Test statistic 
LVSD 2.3 (.28) 1.9 (1.1) 2.1 (1.1) 1.9 (1.3) ns 
PWT 1.2 (.46) .89 (.65) .93 (.49) 1.1 (.58) ns 
FS 33.3 
(11.9) 
25.1 (17.7) 25.0 
(13.5) 
25.7 (13.3) ns 
IVRT .02 (.01) .03 (.02) .04 (.02) .04 (.02) F(1, 38) = 
9.3**,a 
Note. LVDD = left ventricular diastolic diameter; LVSD = left ventricular systolic 
diameter; PWT = posterior wall thickness; FS = fractional shortening; IVRT = 
isovolumetric relaxation time. 
aMain effect of tumor. 
**p < .01. 
Grip Strength 
Grip strength on Days 0, 8, 14, and 17 of tumor growth was 
normalized to body weight and analyzed using repeated-measures 
ANOVA (data shown in Figure 2). There was a within-subjects effect of 
days on grip strength, F(2.84, 170.24) = 10.6, p < .01, and a 
significant interaction of days and tumor (p < .01). There was a main 
effect of tumor on grip strength, F(1, 60) = 3.97, p = .05, but no 
effect of ubiquinol treatment. Bonferroni comparisons revealed a 
significant difference in grip strength between tumor-bearing and 
control mice as early as Day 8 of tumor growth. 
 
Figure 2. Effect of tumor growth and ubiquinol on grip strength. Main effect of tumor, 
p = .05; main effect of days, p < .01; day-by-tumor interaction, p < .01. For all 
groups, n = 16. 
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VRA 
VRA on Days 0, 8, 14, and 17 of tumor growth was analyzed 
using repeated-measures ANOVA. There was no within-subjects effect 
of days on VRA, but there was a significant interaction between days 
and tumor, F(1.88, 78.86) = 3.39, p = .04. There was a main effect of 
tumor growth, F(1, 42) = 7.40, p < .01, and no effect of ubiquinol on 
VRA (data shown in Figure 3). 
 
Figure 3. Effects of tumor growth and ubiquinol on voluntary running activity. Main 
effect of tumor, p < .01; day-by-tumor interaction, p = .04. CC = control no drug, n = 
11; CU = control/ ubiquinol, n = 12; TC = tumor no drug, n = 12; TU = 
tumor/ubiquinol, n = 11.  
Discussion 
Fatigue (CRF) is a significant problem for patients during and 
after treatment for cancer. The causes of CRF are not clearly 
understood, and no effective treatments are available. The purpose of 
the present study was to examine the effects of the anti-oxidant 
ubiquinol, the reduced form of CoQ10, on muscle wasting, myocardial 
function, and fatigue behaviors in adult female mice inoculated with 
the colon26 tumor cell line. 
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We report that VRA and grip strength progressively declined in 
tumor-bearing mice compared to healthy control animals. By Days 18–
19 of tumor growth, gastrocnemius muscle mass was 20% less and 
body weight was 5% less in tumor-bearing animals than in healthy 
control animals, confirming the targeted effect of tumor growth on 
lean body mass (Martin et al., 2013). These changes in body and 
gastrocnemius muscle weight were not due to anorexia–cachexia 
syndrome, as food and water intake of the tumor-bearing animals did 
not decline during the study period, a finding supported by previous 
reports (Graves et al., 2006; Shadfar et al., 2011; Xu et al., 2011). 
However, others have observed reduced food intake and up to 20% 
body weight loss in this mouse model of tumor-induced muscle 
wasting (Murphy et al., 2012; Tian et al., 2010). This difference in 
findings may be due to differences in duration of tumor growth, C26 
cell line variants (Murphy et al., 2012), or the use of only female mice, 
which have been shown to maintain their food intake and lose a 
smaller percentage of body weight than tumor-bearing male mice 
(Cosper & Leinwand, 2011). Similar sex differences in weight loss have 
also been noted in a rat model of cardiac cachexia (Palus, Akashi, von 
Haehling, Anker, & Springer, 2009). 
In the present study, tumor growth increased serum, muscle, 
and heart levels of IL-6 and TNFR1 compared to tissues from healthy 
control animals. Oxidative stress was increased in heart tissue and the 
gastrocnemius of the tumor-bearing mice; however, levels in the 
gastrocnemius were not significantly different from controls. Tumor 
growth increased the expression of MAFbx, MuRF1, and BNIP3 mRNA 
only in the gastrocnemius muscle and not in the heart, as has also 
been described by others (Cosper & Leinwand, 2011). These data 
suggest that increased UPP activity may be an early driver of protein 
degradation in skeletal muscle but not in the heart. This idea is 
supported by our observation that tumor growth was associated with 
loss of skeletal muscle mass but had no effect on heart mass, a finding 
that has also been reported by others (Muhlfeld et al., 2011; Xu et al., 
2011). Others have observed tumor-induced cardiac atrophy in male 
animals (Tian et al., 2011; Wysong et al., 2011) but not in females 
(Cosper & Leinwand, 2011; Muhlfeld et al., 2011). Several studies 
have demonstrated increased UPP activity in hearts of tumor-bearing 
mice (Tian et al., 2011; Wysong et al., 2011), including female mice 
(Shadfar et al., 2011; Xu et al., 2011). It should also be noted that, in 
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previous studies, cardiac atrophy more often occurred in mice that had 
lost up to 20% of body weight, while mice in the present study had 
lost an average of only 5% of body weight. Further research is needed 
to clarify the effects of sex, UPP activity, and progressive weight loss 
on cardiac atrophy in tumor-bearing animals. 
The negative effects of cancer treatment on myocardial function 
have been known for years (Curigliano et al., 2010). Evidence 
indicating a direct effect of tumor growth on myocar-dial function, 
however, has only recently been described in the literature. We and 
others have reported increased LVSD, decreased FS, and decreased 
PWT in tumor-bearing rodents (Shadfar et al., 2011; Tian et al., 2010, 
2011; Wysong et al., 2011; Xu et al., 2011). Others have observed no 
effects of tumor growth on myocardial function in tumor-bearing mice 
(Cosper & Leinwand, 2011; Muhlfeld et al., 2011). While we found no 
evidence of systolic dysfunction in the present study, we did find 
evidence of increased IVRT, indicating diastolic dysfunction. This 
finding is supported by our prior report of prolonged relaxation in 
cardiomyocytes isolated from hearts of tumor-bearing mice (Xu et al., 
2011). Prolonged IVRT is not normally associated with compromised 
oxygen status in the heart, which could affect effort tolerance such as 
VRA or grip strength. However, alterations in diastolic function (or 
diastolic failure) are known to precede systolic dysfunction, particularly 
in cases of diabetic cardiomyopathy (Isfort, Stevens, Shaffer, Jong, & 
Wold, 2014). Further research is needed to understand the role of 
myocardial dysfunction in CRF. 
Treatment with 500 mg/kg/day of ubiquinol in the present study 
had no effect on expression of proinflammatory cytokines in serum, 
gastrocnemius muscle, or heart tissue or on biomarkers of protein 
degradation or oxidative stress in the gastrocnemius muscle or heart. 
This dose was previously shown to reduce inflammatory gene 
transcripts in a mouse model of aging (Schmelzer et al., 2010). Others 
have shown that administration of an antioxidant “cocktail” reduced 
subject reports of fatigue and serum measures of oxidative stress and 
IL-6 and/or TNF-α in cancer patients (Mantovani, Madeddu, & Maccio, 
2012). Because the colon26 tumor cell line constitutively expresses IL-
6, it is possible that the dose of ubiquinol used in the present study 
was inadequate to suppress tumor-induced oxidative stress and 
cytokine production in the context of progressive tumor growth. 
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Surprisingly, ubiquinol increased gastrocnemius muscle mass in 
both the tumor-bearing and healthy control mice. However, muscle 
mass of the tumor-bearing animals treated with ubiquinol was still 
20% less than that of control animals treated with ubiquinol, 
suggesting the anabolic effect of ubiquinol was independent of the 
catabolic effects of tumor growth. The increase in muscle mass, 
however, was not associated with an increase in VRA or grip strength 
in the tumor-bearing mice. Others have reported that treatment with 
perindopril, an angiotensin-converting enzyme inhibitor, improved grip 
strength and locomotor activity of tumor-bearing mice but did not 
improve muscle mass (Murphy, Chee, Trieu, Naim, & Lynch, 2013). 
These data suggest that loss of muscle mass does not explain the 
tumor-induced decrease in VRA and grip strength in this mouse model 
of CRF. 
Behavioral measures of fatigue, such as VRA and grip strength, 
require voluntary engagement in the behavior as well as physical 
ability. In this regard, proinflammatory cytokines have negative effects 
on mood and cognition (Haroon, Raison, & Miller, 2012; Silverman et 
al., 2010; Wood & Weymann, 2013). CRF often co-occurs with 
depressed mood (Pertl et al., 2013). A recent report described no 
effect of tumor growth on spontaneous movement of tumor-bearing 
mice in the home cage but a significant decrease in motor activity 
during the tail suspension test, which is used to model resignation, a 
depressive-like behavior in mice. The increased resignation was 
associated with increased cytokine expression in the hippocampus of 
tumor-bearing mice (Yang et al., 2014). Further research is needed to 
unravel the associations among decreased physical activity, effort 
tolerance, and negative mood in patients with CRF. 
In summary, we reported that treatment with the antioxidant 
ubiquinol improved gastrocnemius muscle mass in both tumor-bearing 
and control mice but had no effect on biomarkers of protein 
degradation, inflammation, or oxidative stress in the gastrocnemius 
muscle or heart of tumor-bearing mice or on behavioral measures of 
fatigue. These data suggest that antioxidant treatment alone is not 
likely to reduce fatigue in cancer patients. 
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